Scarica l'app Stockscreener
9.90
1.79%
-0.18
Precedente Chiudi:
$10.08
Aprire:
$9.85
Volume 24 ore:
252.60K
Relative Volume:
1.12
Capitalizzazione di mercato:
$534.44M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-5.98%
1M Prestazione:
-33.47%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$9.60
$10.46
Intervallo di 1 settimana:
$9.46
$11.14
Portata 52W:
$9.46
$16.50
Eikon Therapeutics Inc Stock (EIKN) Company Profile
Nome
Eikon Therapeutics Inc
Settore
Industria
Telefono
341-777-0566
Indirizzo
230 HARRIET TUBMAN WAY, MILLBRAE
Compare EIKN vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EIKN
Eikon Therapeutics Inc
|
9.90 | 534.44M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Eikon Therapeutics Inc Stock (EIKN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-02 | Iniziato | BofA Securities | Buy |
| 2026-03-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2026-03-02 | Iniziato | JP Morgan | Overweight |
| 2026-03-02 | Iniziato | Mizuho | Outperform |
| 2026-03-02 | Iniziato | Morgan Stanley | Overweight |
| 2026-02-26 | Iniziato | Wedbush | Underperform |
Mostra tutto
Eikon Therapeutics Inc Borsa (EIKN) Ultime notizie
EIKN: Eikon Therapeutics, Inc.Comparative Chart - Zacks Investment Research
Eikon Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Mizuho reiterates Eikon Therapeutics stock rating on pipeline update By Investing.com - Investing.com India
Mizuho reiterates Eikon Therapeutics stock rating on pipeline update - Investing.com
IPO Tracker 2026: Biotech Mega-Rounder Kailera Seeks IPO - BioSpace
Eikon Therapeutics Reports 2025 Financial Results, Upsized IPO, and Key Clinical Pipeline Progress - Minichart
Eikon Therapeutics Reports Q4 and Full Year 2025 Results, Provides Clinical Updates - National Today
Eikon Therapeutics Announces Fourth Quarter And Full Year 2025 Financial Results And Provides Clinical And Corporate Updates - TradingView
Eikon Therapeutics: Advancing Biopharmaceutical Innovation with Proprietary Technology Platform and Clinical-Stage Oncology Pipeline - minichart.com.sg
Eikon Therapeutics Announces Fourth Quarter and Full Year - GlobeNewswire
After a $381M IPO, Eikon fully enrolls a stage 4 lung cancer study - Stock Titan
Eikon Therapeutics (NASDAQ: EIKN) posts 2025 loss but extends cash runway - Stock Titan
Eikon Therapeutics, Inc.(NasdaqGS: EIKN) added to S&P TMI Index - MarketScreener
Eikon Therapeutics (EIKN) Stock Analysis Report | Financials & Insights - Benzinga Japan
Eikon Therapeutics (EIKN) grants 25,873-share stock option award to director - Stock Titan
Eikon Therapeutics (EIKN) grants director Kenneth Frazier 25,873 options - Stock Titan
Large stock option grant to Eikon Therapeutics (EIKN) director and officer - Stock Titan
Eikon Therapeutics Shares Jump 6% as Brokerages Initiate Coverage By Investing.com - Investing.com Canada
Eikon Therapeutics Shares Jump 6% as Brokerages Initiate Coverage - Investing.com UK
BofA initiates Eikon Therapeutics stock with buy rating on platform potential - Investing.com Australia
BofA Securities Initiates Eikon Therapeutics at Buy With $34 Price Target - marketscreener.com
Cantor Fitzgerald Initiates Eikon Therapeutics at Overweight - marketscreener.com
This NextTrip Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Mizuho Initiates Eikon Therapeutics at Outperform With $26 Price Target - marketscreener.com
BofA initiates Eikon Therapeutics stock with buy rating on platform potential By Investing.com - Investing.com South Africa
Morgan Stanley Initiates Eikon Therapeutics at Overweight With $32 Price Target - marketscreener.com
Mizuho initiates Eikon Therapeutics stock coverage with outperform - Investing.com Nigeria
JPMorgan initiates Eikon Therapeutics stock at Overweight By Investing.com - Investing.com Nigeria
Morgan Stanley initiates Eikon Therapeutics stock coverage at overweight By Investing.com - Investing.com South Africa
Morgan Stanley initiates Eikon Therapeutics stock coverage at overweight - Investing.com India
JPMorgan initiates Eikon Therapeutics stock at Overweight - Investing.com
Bank of America Global Research recently announced the official initiation of research coverage on biotechnology company Eikon Therapeutics (stock code: EIKN), and assigned an initial "Buy" rating. - Bitget
Bay Area life sciences firms raise $6.1B as three companies go public - The Business Journals
Eikon Therapeutics, Inc.Common Stock (NQ: EIKN - The Chronicle-Journal
Eikon Therapeutics, Inc.: Dividend historical data and projections - marketscreener.com
Eikon Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | EIKN | US2825641036 - marketscreener.com
Eikon Therapeutics stock drops after Wedbush downgrade By Investing.com - Investing.com Australia
Eikon Therapeutics stock drops after Wedbush downgrade - Investing.com South Africa
Wedbush initiates Eikon Therapeutics stock with underperform rating - Investing.com South Africa
Wedbush initiates Eikon Therapeutics stock with underperform rating By Investing.com - Investing.com Australia
User - The Chronicle-Journal
EIKN Should I Buy - Intellectia AI
ADIA and Platinum Falcon disclose 2.82M EIKN shares (ADIA affiliate ownership) - Stock Titan
EIKN SEC FilingsEikon Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
What is the current Price Target and Forecast for Eikon Therapeutics, Inc. (EIKN) - Zacks Investment Research
Insider Stock Purchases: February 10, 2026 - Quiver Quantitative
Eikon Therapeutics Prices $381 Million Initial Public Offering - Global Legal Chronicle
Eikon Therapeutics Inc Azioni (EIKN) Dati Finanziari
Non sono disponibili dati finanziari per Eikon Therapeutics Inc (EIKN). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):